WASHINGTON, June 1, 2026 /PRNewswire/ -- In recognition of SVT Awareness Day, the Heart Rhythm Society (HRS) and Milestone Pharmaceuticals are partnering to expand supraventricular tachycardia (SVT) ...
MADISON, WI — The American College of Cardiology, American Heart Association, and the Heart Rhythm Society (ACC/AHA/HRS) have published new guidelines for the management of patients with ...
Pulmonary hypertension (PH) is a progressive disease characterized by vascular proliferation and remodeling in the pulmonary vasculature. In recent years, various treatments have been introduced that ...
Untreated or unmanaged, SVT can lead to other possibly fatal heart abnormalities. Patients are advised to practice a cardiac-friendly diet and lifestyle (low sodium, little to no caffeine or alcohol, ...
AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK(R) (landiolol) for use in pediatric patients (from birth to <18 years of age) with ...
(HealthDay News) — For patients with symptomatic supraventricular tachycardia (SVT), caffeine is associated with increases in systolic and diastolic blood pressure, but does not impact cardiac ...
Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...
A recent study published in Pacing and Clinical Electrophysiology (PACE) determined that the use of catheter ablation to treat supraventricular tachycardia (SVT) is not detrimental to patients. This ...
A drug approved to treat chest pain reduces the incidence of a common arrhythmia called ventricular tachycardia in patients with an implantable cardioverter defibrillator (ICD), according to a study ...
These new resources to help patients and caregivers better understand SVT, recognize symptoms, and navigate conversations about treatment with their healthcare team. An estimated two million Americans ...
AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK® (landiolol) for use in pediatric patients (from birth to <18 years of age) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results